{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:33:49Z","timestamp":1789612429041,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82303777"],"award-info":[{"award-number":["82303777"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Key Research and Development Program of China","award":["2022YFC2406704"],"award-info":[{"award-number":["2022YFC2406704"]}]},{"name":"the National Key R&D Program of China","award":["2023YFA0915400"],"award-info":[{"award-number":["2023YFA0915400"]}]},{"name":"the National Key Research and Development Program of China","award":["2021YFA1201102"],"award-info":[{"award-number":["2021YFA1201102"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["32370973"],"award-info":[{"award-number":["32370973"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-025-03833-w","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T14:24:18Z","timestamp":1766413458000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dual-functional nanovesicles simultaneously inhibit stromal fibrosis and angiogenesis to suppress cholangiocarcinoma progression"],"prefix":"10.1186","volume":"23","author":[{"given":"Lijing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixi","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiying","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fazhan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqiao","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianjiao","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihai","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"3833_CR1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","volume":"2","author":"SI Ilyas","year":"2018","unstructured":"Ilyas SI, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;2:95\u2013111.","journal-title":"Nat Rev Clin Oncol"},{"key":"3833_CR2","doi-asserted-by":"crossref","unstructured":"Cillo U, Fondevila C, Donadon M, Gringeri E, Mocchegiani F, Schlitt HJ et al. Surgery for Cholangiocarcinoma. 2019;1:143\u201355.","DOI":"10.1111\/liv.14089"},{"key":"3833_CR3","doi-asserted-by":"publisher","first-page":"100737","DOI":"10.1016\/j.aohep.2022.100737","volume":"5","author":"A Elvevi","year":"2022","unstructured":"Elvevi A, Laffusa A, Scaravaglio M, Rossi RE, Longarini R, Stagno AM, et al. Clinical treatment of cholangiocarcinoma: an updated comprehensive review. Ann Hepatol. 2022;5:100737.","journal-title":"Ann Hepatol"},{"key":"3833_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","volume":"1","author":"PJ Brindley","year":"2021","unstructured":"Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, et al. Cholangiocarcinoma Nat Reviews Disease Primers. 2021;1:65.","journal-title":"Cholangiocarcinoma Nat Reviews Disease Primers"},{"key":"3833_CR5","doi-asserted-by":"crossref","unstructured":"Marin JJG, Lozano E, Herraez E, Asensio M, Di Giacomo S, Romero MR et al. Chemoresistance and chemosensitization in cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis. 2018;4:1444\u201353.","DOI":"10.1016\/j.bbadis.2017.06.005"},{"key":"3833_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.850732","volume":"12","author":"Q Zheng","year":"2022","unstructured":"Zheng Q, Zhang B, Li C, Zhang X. Overcome drug resistance in cholangiocarcinoma: new insight into mechanisms and refining the preclinical experiment models. Front Oncol. 2022;12:850732.","journal-title":"Front Oncol"},{"key":"3833_CR7","first-page":"198","volume":"2","author":"D Moris","year":"2023","unstructured":"Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky M. E. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin. 2023;2:198\u2013222.","journal-title":"CA Cancer J Clin"},{"key":"3833_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/hep.31410","volume":"Suppl 1","author":"L Fabris","year":"2021","unstructured":"Fabris L, Sato K, Alpini G, Strazzabosco M. The tumor microenvironment in cholangiocarcinoma progression. Hepatology. 2021;1:75\u201385.","journal-title":"Hepatology"},{"key":"3833_CR9","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.3390\/ijms23084187","volume":"8","author":"S Mancarella","year":"2022","unstructured":"Mancarella S, Serino G, Coletta S, Armentano R, Dituri F, Ardito F, et al. The tumor microenvironment drives intrahepatic cholangiocarcinoma progression. Int J Mol Sci. 2022;8:4187.","journal-title":"Int J Mol Sci"},{"key":"3833_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2015.08.022","author":"E Lozano","year":"2015","unstructured":"Lozano E, Monte MJ, Briz O, Hern\u00e1ndez-Hern\u00e1ndez A, Banales JM, Marin JJ, et al. Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT). J Control Release. 2015;216:93\u2013102. https:\/\/doi.org\/10.1016\/j.jconrel.2015.08.022.","journal-title":"J Control Release"},{"key":"3833_CR11","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1097\/HEP.0000000000000206","volume":"4","author":"Vil\u00e0P Cantallops","year":"2024","unstructured":"Cantallops Vil\u00e0P, Ravichandra A, Agirre Lizaso A, Perugorria MJ, Aff\u00f2 S. Heterogeneity, crosstalk, and targeting of cancer-associated fibroblasts in cholangiocarcinoma. Hepatology. 2024;4:941\u201358.","journal-title":"Hepatology"},{"key":"3833_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.777617","volume":"11","author":"Y Wang","year":"2021","unstructured":"Wang Y, Chen T, Li K, Mu W, Liu Z, Shi A, et al. Recent advances in the mechanism research and clinical treatment of anti-angiogenesis in biliary tract cancer. Front Oncol. 2021;11:777617.","journal-title":"Front Oncol"},{"key":"3833_CR13","doi-asserted-by":"crossref","unstructured":"Benmebarek MR, Oguz C, Seifert M, Ruf B, Myojin Y, Bauer KC et al. Anti-vascular endothelial growth factor treatment potentiates immune checkpoint Blockade through a BAFF- and IL-12-dependent reprogramming of the TME. Immunity. 2025;4:926\u201345.","DOI":"10.1016\/j.immuni.2025.02.017"},{"key":"3833_CR14","first-page":"4187","volume":"8","author":"S Mancarella","year":"2022","unstructured":"Mancarella S, Serino G. Tumor Microenvironment Drives Intrahepatic Cholangiocarcinoma Progression. 2022;8:4187.","journal-title":"Tumor Microenvironment Drives Intrahepatic Cholangiocarcinoma Progression"},{"key":"3833_CR15","first-page":"411","volume":"4","author":"A Casadei-Gardini","year":"2021","unstructured":"Casadei-Gardini A. Angiogenesis in biliary tract cancer: targeting and therapeutic potential. Expert Opin Investig Drugs. 2021;4:411\u201318.","journal-title":"Expert Opin Investig Drugs"},{"key":"3833_CR16","doi-asserted-by":"crossref","unstructured":"Pasquier E, Honor\u00e9 S, Braguer D. Microtubule-targeting agents in angiogenesis: where do we stand? Drug Resist Updat. 2006;9:74\u201386.","DOI":"10.1016\/j.drup.2006.04.003"},{"key":"3833_CR17","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1038\/nm.4197","volume":"11","author":"S Frentzas","year":"2016","unstructured":"Frentzas S, Simoneau E, Bridgeman VL, Vermeulen PB, Foo S, Kostaras E, et al. Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. Nat Med. 2016;11:1294\u2013302.","journal-title":"Nat Med"},{"key":"3833_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-022-02511-7","volume":"1","author":"C Cai","year":"2022","unstructured":"Cai C, Wang X, Fu Q, Chen A. The VEGF expression associated with prognosis in patients with intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. World J Surg Oncol. 2022;1:40.","journal-title":"World J Surg Oncol"},{"key":"3833_CR19","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.ccell.2020.05.005","volume":"6","author":"Y Shen","year":"2020","unstructured":"Shen Y, Wang X, Lu J, Salfenmoser M, Wirsik NM, Schleussner N, et al. Reduction of liver metastasis stiffness improves response to bevacizumab in metastatic colorectal cancer. Cancer Cell. 2020;6:800\u2013e177.","journal-title":"Cancer Cell"},{"key":"3833_CR20","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1158\/0008-5472.CAN-13-2800","volume":"4","author":"KY Aguilera","year":"2014","unstructured":"Aguilera KY, Rivera LB, Hur H, Carbon JG, Toombs JE, Goldstein CD, et al. Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma. Cancer Res. 2014;4:1032\u201344.","journal-title":"Cancer Res"},{"key":"3833_CR21","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1002\/hep.26762","volume":"6","author":"AE Sirica","year":"2014","unstructured":"Sirica AE, Gores GJ. Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting. Hepatology. 2014;6:2397\u2013402.","journal-title":"Hepatology"},{"key":"3833_CR22","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.jcmgh.2023.01.006","volume":"4","author":"F Ying","year":"2023","unstructured":"Ying F, Chan MSM, Lee TK. W. Cancer-Associated fibroblasts in hepatocellular carcinoma and cholangiocarcinoma. Cell Mol Gastroenterol Hepatol. 2023;4:985\u201399.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"3833_CR23","doi-asserted-by":"crossref","unstructured":"Cantallops Vil\u00e0P, Ravichandra A. Heterogeneity, crosstalk, and targeting of cancer-associated fibroblasts in cholangiocarcinoma. Hepatology. 2024;4:941\u201358.","DOI":"10.1097\/HEP.0000000000000206"},{"key":"3833_CR24","doi-asserted-by":"crossref","unstructured":"Czekay RP, Higgins CE, Aydin HB, Samarakoon R, Subasi NB, Higgins SP et al. SERPINE1: Role in Cholangiocarcinoma Progression and a Therapeutic Target in the Desmoplastic Microenvironment. 2024; 10: 796.","DOI":"10.3390\/cells13100796"},{"key":"3833_CR25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12876-025-03829-8","volume":"1","author":"C Ni","year":"2025","unstructured":"Ni C, Hua R, Yang Y, Liang J, Liu W, Wang L, et al. Single-cell transcriptomic analysis reveals prognosis-related stromal signatures that potentiate stratification of patients with extrahepatic cholangiocarcinoma. BMC Gastroenterol. 2025;1:235.","journal-title":"BMC Gastroenterol"},{"key":"3833_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.trecan.2018.01.007","volume":"3","author":"D H\u00f8gdall","year":"2018","unstructured":"H\u00f8gdall D, Lewinska M, Andersen JB. Desmoplastic tumor microenvironment and immunotherapy in cholangiocarcinoma. Trends Cancer. 2018;3:239\u201355.","journal-title":"Trends Cancer"},{"key":"3833_CR27","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.jhep.2012.06.012","volume":"4","author":"A Gentilini","year":"2012","unstructured":"Gentilini A, Rombouts K, Galastri S, Caligiuri A, Mingarelli E, Mello T, et al. Role of the stromal-derived factor-1 (SDF-1)-CXCR4 axis in the interaction between hepatic stellate cells and cholangiocarcinoma. J Hepatol. 2012;4:813\u201320.","journal-title":"J Hepatol"},{"key":"3833_CR28","doi-asserted-by":"crossref","unstructured":"Affo S, Nair A, Brundu F, Ravichandra A, Bhattacharjee S, Matsuda M et al. Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. Cancer Cell. 2021;6:866\u201382.","DOI":"10.1016\/j.ccell.2021.03.012"},{"key":"3833_CR29","doi-asserted-by":"crossref","unstructured":"Martin-Serrano MA, Kepecs B, Torres-Martin M, Bramel ER, Haber PK, Merritt E et al. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. Gut. 2023;4:736\u201348.","DOI":"10.1136\/gutjnl-2021-326514"},{"key":"3833_CR30","first-page":"957","volume":"4","author":"C Chuaysri","year":"2009","unstructured":"Chuaysri C, Thuwajit P, Paupairoj A, Chau-In S, Suthiphongchai T, Thuwajit C. Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma. Oncol Rep. 2009;4:957\u201369.","journal-title":"Oncol Rep"},{"key":"3833_CR31","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3892\/ol.2013.1720","volume":"2","author":"JG Parikh","year":"2014","unstructured":"Parikh JG, Kulkarni A, Johns C. \u03b1-smooth muscle actin-positive fibroblasts correlate with poor survival in hepatocellular carcinoma. Oncol Lett. 2014;2:573\u20135.","journal-title":"Oncol Lett"},{"key":"3833_CR32","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.apsb.2021.08.011","volume":"2","author":"Y Yan","year":"2022","unstructured":"Yan Y, Du C, Duan X, Yao X, Wan J, Jiang Z, et al. Inhibiting collagen I production and tumor cell colonization in the lung via miR-29a-3p loading of exosome-\/liposome-based nanovesicles. Acta Pharm Sinica B. 2022;2:939\u201351.","journal-title":"Acta Pharm Sinica B"},{"key":"3833_CR33","first-page":"3067","volume":"10","author":"K Kesh","year":"2020","unstructured":"Kesh K, Gupta VK, Durden B, Mateo-Victoriano GV, Lavania B. Therapy Resistance, cancer stem cells and ECM in cancer. Matrix Reloaded. 2020;10:3067.","journal-title":"Matrix Reloaded"},{"key":"3833_CR34","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrc.2017.51","volume":"8","author":"M De Palma","year":"2017","unstructured":"De Palma M, Biziato D, Petrova TV. Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 2017;8:457\u201374.","journal-title":"Nat Rev Cancer"},{"key":"3833_CR35","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrd.2015.17","volume":"6","author":"N Ferrara","year":"2016","unstructured":"Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;6:385\u2013403.","journal-title":"Nat Rev Drug Discov"},{"key":"3833_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00221","volume":"10","author":"Y Haibe","year":"2020","unstructured":"Haibe Y, Kreidieh M, El Hajj H, Khalifeh I, Mukherji D, Temraz S, et al. Resistance mechanisms to anti-angiogenic therapies in cancer. Front Oncol. 2020;10:221.","journal-title":"Front Oncol"},{"key":"3833_CR37","first-page":"584","volume":"7","author":"G Pag\u00e8s","year":"2020","unstructured":"Pag\u00e8s G. Resistance to anti-angiogenic therapies: a mechanism depending on the time of exposure to the drugs. Front Cell Dev Biology. 2020;7:584.","journal-title":"Front Cell Dev Biology"},{"key":"3833_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2018.09.031","author":"DF Mardhian","year":"2018","unstructured":"Mardhian DF, Storm G, Bansal R, Prakash J. Nano-targeted relaxin impairs fibrosis and tumor growth in pancreatic cancer and improves the efficacy of gemcitabine in vivo. J Control Release. 2018;290:1\u201310. https:\/\/doi.org\/10.1016\/j.jconrel.2018.09.031.","journal-title":"J Control Release"},{"key":"3833_CR39","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1038\/s41467-019-10893-8","volume":"1","author":"M Hu","year":"2019","unstructured":"Hu M, Wang Y, Xu L, An S, Tang Y, Zhou X, et al. Relaxin gene delivery mitigates liver metastasis and synergizes with check point therapy. Nat Commun. 2019;1:2993.","journal-title":"Nat Commun"},{"key":"3833_CR40","doi-asserted-by":"publisher","first-page":"2208404","DOI":"10.1002\/adfm.202208404","volume":"47","author":"L Zhang","year":"2022","unstructured":"Zhang L, Li Z, Wang F, Chen Q, Zu M, Li X, et al. Integrin-enriched membrane nanocarrier for the specific delivery of RGD\u2010modified relaxin analog to inhibit pancreatic cancer liver metastasis through reversing hepatic stellate cell activation. Adv Funct Mater. 2022;47:2208404.","journal-title":"Adv Funct Mater"},{"key":"3833_CR41","doi-asserted-by":"crossref","unstructured":"Lang J, Zhao X, Qi Y, Zhang Y, Han X. Reshaping prostate tumor microenvironment to suppress metastasis via Cancer-Associated fibroblast inactivation with Peptide-Assembly-Based nanosystem. ACS Nano. 2019;11:12357\u201371.","DOI":"10.1021\/acsnano.9b04857"},{"key":"3833_CR42","doi-asserted-by":"crossref","unstructured":"Li A, Zhu L, Lei N, Wan J, Duan X, Liu S et al. S100A4-dependent Glycolysis promotes lymphatic vessel sprouting in tumor. Angiogenesis. 2023;1:19\u201336.","DOI":"10.1007\/s10456-022-09845-6"},{"key":"3833_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113931","author":"C Pacheco","year":"2025","unstructured":"Pacheco C, de Dios O, Ramir\u00e9z-Gonz\u00e1lez MA, Martins C, Fialho SL, Baltazar F, et al. Multimodal nanoparticles co-delivering bevacizumab and dichloroacetate for dual targeting of neoangiogenesis and hyperglycolysis in glioblastoma treatment. J Control Release. 2025;384:113931. https:\/\/doi.org\/10.1016\/j.jconrel.2025.113931.","journal-title":"J Control Release"},{"key":"3833_CR44","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1158\/0008-5472.CAN-23-0025","volume":"21","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Zhou R, Cai J, Yang N, Wen Z, Zhang Z, et al. Matrix stiffness triggers lipid metabolic Cross-talk between tumor and stromal cells to mediate bevacizumab resistance in colorectal cancer liver metastases. Cancer Res. 2023;21:3577\u201392.","journal-title":"Cancer Res"},{"key":"3833_CR45","doi-asserted-by":"publisher","first-page":"e2108817","DOI":"10.1002\/adma.202108817","volume":"12","author":"M Hou","year":"2022","unstructured":"Hou M, Wei Y, Zhao Z, Han W, Zhou R, Zhou Y, et al. Immuno-Engineered nanodecoys for the Multi-Target Anti-Inflammatory treatment of autoimmune diseases. Adv Mater. 2022;12:e2108817.","journal-title":"Adv Mater"},{"key":"3833_CR46","doi-asserted-by":"publisher","first-page":"10980","DOI":"10.1073\/pnas.1106634108","volume":"27","author":"CM Hu","year":"2011","unstructured":"Hu CM, Zhang L, Aryal S, Cheung C, Fang RH, Zhang L. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci U S A. 2011;27:10980\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3833_CR47","first-page":"3055","volume":"3","author":"FT Wang","year":"2019","unstructured":"Wang FT, Sun W, Zhang JT, Fan YZ. Cancer-associated fibroblast regulation of tumor neo-angiogenesis as a therapeutic target in cancer. Oncol Lett. 2019;3:3055\u201365.","journal-title":"Oncol Lett"},{"key":"3833_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100849","author":"M Huang","year":"2022","unstructured":"Huang M, Lin Y, Wang C, Deng L, Chen M, Assaraf YG, et al. New insights into antiangiogenic therapy resistance in cancer: mechanisms and therapeutic aspects. Drug Resist Updat. 2022;64:100849. https:\/\/doi.org\/10.1016\/j.drup.2022.100849.","journal-title":"Drug Resist Updat"},{"key":"3833_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2022.07.015","author":"R Shen","year":"2022","unstructured":"Shen R, Peng L, Zhou W, Wang D, Jiang Q, Ji J, et al. Anti-angiogenic nano-delivery system promotes tumor vascular normalizing and micro-environment reprogramming in solid tumor. J Control Release. 2022;349:550\u201364. https:\/\/doi.org\/10.1016\/j.jconrel.2022.07.015.","journal-title":"J Control Release"},{"key":"3833_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ntm.2024.100036","author":"P Ma","year":"2024","unstructured":"Ma P, Wang G, Men K, Li C, Gao N, Li L. Advances in clinical application of nanoparticle-based therapy for cancer treatment: a systematic review. Nano TransMed. 2024;3:100036. https:\/\/doi.org\/10.1016\/j.ntm.2024.100036.","journal-title":"Nano TransMed"},{"key":"3833_CR51","doi-asserted-by":"publisher","first-page":"5091","DOI":"10.1021\/acsnano.8b08142","volume":"5","author":"L Zhang","year":"2019","unstructured":"Zhang L, Qi Y, Min H, Ni C, Wang F, Wang B, et al. Cooperatively responsive peptide nanotherapeutic that regulates angiopoietin receptor Tie2 activity in tumor microenvironment to prevent breast tumor relapse after chemotherapy. ACS Nano. 2019;5:5091\u2013102.","journal-title":"ACS Nano"},{"key":"3833_CR52","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.trecan.2022.03.001","volume":"7","author":"PE Saw","year":"2022","unstructured":"Saw PE, Chen J, Song E. Targeting CAFs to overcome anticancer therapeutic resistance. Trends Cancer. 2022;7:527\u201355.","journal-title":"Trends Cancer"},{"key":"3833_CR53","doi-asserted-by":"publisher","first-page":"e2303814","DOI":"10.1002\/advs.202303814","volume":"32","author":"ZW Chen","year":"2023","unstructured":"Chen ZW, Kang FP, Xie CK, Liao CY, Li G, Wu YD, et al. A novel Trojan horse nanotherapy strategy targeting the cPKM-STMN1\/TGFB1 axis for effective treatment of intrahepatic cholangiocarcinoma. Adv Sci (Weinh). 2023;32:e2303814.","journal-title":"Adv Sci (Weinh)"},{"key":"3833_CR54","doi-asserted-by":"publisher","first-page":"e2005155","DOI":"10.1002\/adma.202005155","volume":"15","author":"P Liang","year":"2021","unstructured":"Liang P, Ballou B, Lv X, Si W, Bruchez MP, Huang W, et al. Monotherapy and combination therapy using Anti-Angiogenic nanoagents to fight cancer. Adv Mater. 2021;15:e2005155.","journal-title":"Adv Mater"},{"key":"3833_CR55","doi-asserted-by":"crossref","unstructured":"Ji T, Lang J, Wang J, Cai R, Zhang Y, Qi F et al. Designing liposomes to suppress extracellular matrix expression to enhance drug penetration and pancreatic tumor therapy. ACS Nano. 2017;9:8668\u201378.","DOI":"10.1021\/acsnano.7b01026"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03833-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-025-03833-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03833-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T03:02:38Z","timestamp":1766458958000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-025-03833-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3833"],"URL":"https:\/\/doi.org\/10.1186\/s12951-025-03833-w","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"16 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) and Research Ethics Committee of the First Affiliated Hospital of Zhengzhou University (approval number: 2024-KY-1113-001).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"781"}}